Alivus Life Sciences Ltd (ALIVUS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543322 | NSE: ALIVUS | Pharmaceuticals & Drugs | Small Cap

Alivus Life Sciences Share Price

883.20 12.60 1.45%
as on 05-Dec'25 16:59

Alivus Life Sciences Ltd (ALIVUS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 543322 | NSE: ALIVUS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Alivus Life Sciences

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Alivus Life Sciences stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
20.14
Market Cap:
10,680.6 Cr.
52-wk low:
827.1
52-wk high:
1,259.8

Is Alivus Life Sciences Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Alivus Life Sciences: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alivus Life Sciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 0%0%0%527.7%185.6%96.8%42.2%30%28.3%25.5%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 000.38861,5371,8852,1232,1612,2832,3872,481
Sales YoY Gr.-NANA3,54,468%73.4%22.6%12.6%1.8%5.6%4.5%-
Adj EPS 00-7.918.628.432.933.837.438.539.143.2
YoY Gr.-NANANA52.5%15.8%2.7%10.7%3%1.5%-
BVPS (₹) 00-25.48.237.369.8167.4174189.5229.1245.8
Adj Net
Profit
00-0.4201306354414458472479530
Cash Flow from Ops. 00-0.510.4195388598306414392-
Debt/CF from Ops. 0000000000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA9.2%4%4.5%
Adj EPS NA6.6%5%1.5%
BVPSNA43.8%11%20.9%
Share Price - - 26.5% -17.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
0031462.912561.429.521.921.118.618.2
Op. Profit
Mgn %
00-5.228.730.831.629.129.729.628.729.8
Net Profit
Mgn %
00-17522.719.918.819.521.220.720.121.4
Debt to
Equity
00000000000
Working Cap
Days
000193248258271311349340176
Cash Conv.
Cycle
000123160151134131137151141

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Alivus Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 43.2 -
TTM Sales (₹ Cr.) 2,481 -
BVPS (₹.) 245.8 -
Reserves (₹ Cr.) 2,991 -
P/BV 3.54 -
PE 20.14 -
From the Market
52 Week Low / High (₹) 827.10 / 1259.75
All Time Low / High (₹) 369.00 / 1335.00
Market Cap (₹ Cr.) 10,681
Equity (₹ Cr.) 24.5
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Alivus Life Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.009.479.479.479.470.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Alivus Life Sciences - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Alivus Life Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales08861,5371,8852,1232,1612,2832,387
Operating Expenses 06391,0651,2941,5071,5191,6091,704
Manufacturing Costs0135185182225253276295
Material Costs03326648771,0199849691,037
Employee Cost 0106142149169180258252
Other Costs 066748694102106121
Operating Profit -0247472591616642674683
Operating Profit Margin (%) -5.2%27.9%30.7%31.4%29.0%29.7%29.5%28.6%
Other Income 0112115291235
Interest 01348828122
Depreciation 019293338425361
Exceptional Items 00000000
Profit Before Tax -0228421471565629631654
Tax 033108119146162160169
Profit After Tax -0196313352419467471486
PAT Margin (%) -175.0%22.1%20.4%18.6%19.7%21.6%20.6%20.3%
Adjusted EPS (₹)-7.918.129.032.634.238.138.439.6
Dividend Payout Ratio (%)0%0%0%0%61%55%59%13%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund -1884027532,0512,1322,3212,807
Share Capital 022225252525
Reserves -1864007512,0262,1072,2972,783
Minority Interest00000000
Debt00000000
Long Term Debt00000000
Short Term Debt00000000
Trade Payables0183201221308427369390
Others Liabilities 11,2041,1231,247475662838556
Total Liabilities 01,4751,7262,2212,8343,2203,5283,754

Fixed Assets

Gross Block04765956527069361,0121,219
Accumulated Depreciation0194979116156207264
Net Fixed Assets 0456546573590781805955
CWIP 08011149762106102
Investments 0000000478
Inventories0401413513516604667674
Trade Receivables0448639620673807765970
Cash Equivalents 021011651230930271
Others Assets 088107385445658883504
Total Assets 01,4751,7262,2212,8343,2203,5283,754

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity -010195388598306414392
PBT -0228421471565629631654
Adjustment 0-1015713371457981
Changes in Working Capital -0-93-190-108100-214-134-180
Tax Paid 0-24-93-109-138-154-163-163
Cash Flow From Investing Activity 0-9-51-69-122-147-116-616
Capex 0-9-51-66-132-163-129-166
Net Investments 000-3300-470
Others 00007161220
Cash Flow From Financing Activity 01-137-214-79-388-279-6
Net Proceeds from Shares 02001,012001
Net Proceeds from Borrowing 00000000
Interest Paid 0000-28-1-2-2
Dividend Paid 0000-129-386-2760
Others 0-1-137-214-934-1-2-4
Net Cash Flow 028106397-22818-230

Finance Ratio

PARTICULARSMar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)N/A451.05127.8460.9129.8722.3321.1518.94
ROCE (%)N/A527.74185.696.7542.2430.0128.3125.5
Asset Turnover Ratio2.921.20.960.960.840.720.680.66
PAT to CFO Conversion(x)N/A0.050.621.11.430.660.880.81
Working Capital Days
Receivable Days4692129122111124125132
Inventory Days568396898894101102
Payable Days1031011068895136150134

Alivus Life Sciences Ltd Stock News

Alivus Life Sciences Ltd FAQs

The current trading price of Alivus Life Sciences on 05-Dec-2025 16:59 is ₹883.2.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Alivus Life Sciences stood at ₹10,680.6.
The latest P/E ratio of Alivus Life Sciences as of 04-Dec-2025 is 20.14.
The latest P/B ratio of Alivus Life Sciences as of 04-Dec-2025 is 3.54.
The 52-week high of Alivus Life Sciences is ₹1,259.8 and the 52-week low is ₹827.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alivus Life Sciences is ₹2,481 ( Cr.) .

About Alivus Life Sciences Ltd

Glenmark Life Sciences is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes. It also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives and other therapeutic areas. Its API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which reflects its capability to branch into other high value products. It has strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (anti-hypertensive), Teneligliptin (diabetes), Zonisamide (CNS) and Adapalene (dermatology). It are also increasingly providing contract development and manufacturing operations (CDMO) services to a range of multinational and specialty pharmaceutical companies. It is a research and development (R&D)-driven API manufacturer, focused on undertaking dedicated R&D in its existing products and in areas where there is growth potential in the future. Maintaining high standards of process innovation and quality in its R&D and manufacturing operations is critical to its brand and maintenance of long-term relationships with its customers.

The company currently operates four multi-purpose manufacturing facilities which are situated on leasehold properties located at Ankleshwar and Dahej in the state of Gujarat, India, and Mohol and Kurkumbh in the state of Maharashtra, India with an aggregate annual total installed capacity of 726.6 KL as of March 31, 2021. Its R&D laboratories focus on new product development and complex molecules, cost improvement programs, process improvements and oncology product development. To assist it with its R&D initiatives, it has established dedicated teams for new product development, complex products, oncology product development, technology transfer, life cycle management and project management.’ It has a professional and experienced management team. Its management team has demonstrated the ability to successfully build and integrate its businesses with various operating activities through their cumulative years of work experience. In particular, they have led the process through which it has created value through organic growth, built brand recognition and loyalty and identified new business opportunities.

Business area of the company

The company is in the business of making high-quality drugs by unlocking the possibilities of science.

Awards, accreditations and recognitions

  • 2015: Ankleshwar plant received ISO 14001:2015 certifying the management system of manufacturing  facility.
  • 2016: Dahej plant received ISO 14001:2015 certifying the management system of manufacturing facility.
  • 2016: Ankleshwar plant received BS OHSAS 18001:2017 certifying the management system of the manufacturing facility.
  • 2017: Ankleshwar plant was awarded Greentech Safety silver award by the Greentech Foundation for outstanding achievements in safety management.
  • 2018: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Dahej plant received ISO 14001:2015 re-certifying the management system of manufacturing facility.
  • 2018: Ankleshwar plant was awarded Greentech Safety gold award by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Ankleshwar plant was awarded Greentech Safety Award as the winner in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was awarded Greentech Safety Award for the year 2019 as the runner-up in the pharmaceutical sector by the Greentech Foundation for outstanding achievements in safety management.
  • 2019: Dahej plant was declared the winner of the Greentech Environment Award for the year 2019 for outstanding achievements in environment management in the pharmaceutical sector.
  • 2020: Dahej plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2020: Dahej plant was declared the winner of the Greentech Environment Award for the year 2020 for outstanding achievements in environment protection.
  • 2021: Ankleshwar plant received ISO 45001:2018 certifying the management system of the manufacturing facility.
  • 2021: Ankleshwar plant received ISO 14001:2015 re-certifying the management system of the manufacturing facility.

Major events and milestones

  • 2001-2002: Established manufacturing plant at Kurkumbh, Maharashtra.
  • 2001-2002: The company’s Promoter established its API business.
  • 2004: Commenced manufacturing at Mohol, Maharashtra.
  • 2008: Ankleshwar plant at Gujarat inspected by US-FDA.
  • 2012: Ankleshwar plant inspected by PMDA and AFSSAPS.
  • 2013: Commenced manufacturing at Dahej, Gujarat.
  • 2013: Ankleshwar plant inspected by COFEPRIS.
  • 2015: Dahej plant inspected by US-FDA.
  • 2016: Dahej plant inspected by PMDA Japan.
  • 2018: Dahej plant inspected by EDQM, ANSM and US-FDA.
  • 2018: Mohol plant inspected by US-FDA.
  • 2019: The API business was spun off into Company.
  • 2019: Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan.
  • 2021: Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×